Google
AMPH 株価分析 — AMPHASTAR P (Healthcare >> Drug Manufacturers - Specialty & Generic)
AMPH に関するよくある質問
AMPHのPER（株価収益率）は？
AMPHASTAR P（AMPH）は現在PER 11.34倍で取引されています。
AMPHのROE（自己資本利益率）は？
AMPHASTAR PのROEは10.24%です。
AMPHの配当利回りは？
AMPHASTAR Pの配当利回りは0.00%です。
AMPHの品質スコア（Quality Score）は？
当社のAIはAMPHの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
AMPHは今が買い時ですか？
当社AIのタイミングスコアは100点中63点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
AMPHはどのセクターに属しますか？
AMPHASTAR PはHealthcare >> Drug Manufacturers - Specialty & Genericセクターに分類されます（NASDAQ市場）
AMPH AI Analysis Summary
Our AI summary for AMPH: AMPHASTAR P (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 11.34, ROE of 10.24%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 63/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 19.94
Price
-0.44
(-2.16%)
Day Change
|
|
|---|
AMPH, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
666
|
| Magic Formula Rank by ROE |
666
|
| Magic Formula Rank by ROIC |
644
|
| Price | 19.94 |
| PBV / Sector |
1.16 / 3.22
GREAT
|
| Earning Per Share | 1.76 |
| PE / Sector |
11.34 / 29.79
GOOD
|
| PEG or PE/Growth / Sector |
1.02 / 0.13
|
| Average 1M Daily Value |
7.86 M
|
| Average 1W Daily Value |
6.91 M
|
| Timing Factors |
|
57% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:28 |
| Symbol | AMPH |
| Name | AMPHASTAR P |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 44.09 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 898.61 / 10,754.62 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 11570 6th Street, Rancho Cucamonga, CA, United States, 91730
Phone: 909 980 9484
Website: https://www.amphastar.com
Employees: 1,976
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
